瑞舒伐他汀对稳定型心绞痛PCI病人炎症因子影响_医学论文.docVIP

瑞舒伐他汀对稳定型心绞痛PCI病人炎症因子影响_医学论文 瑞舒伐他汀对稳定型心绞痛PCI病人炎症因子影响_医学论文 【摘要】 目的 观察瑞舒伐他汀对稳定型心绞痛病人经皮冠状动脉介入治疗(PCI)术后炎性因子高敏C反应蛋白(hs与白细胞介素的影响。方法 选择在我院行PCI的40例稳定型心绞痛病人为研究对象，随机分为治疗组和对照组，各20例。在常规治疗的基础上，治疗组PCI前7 d开始给予瑞舒伐他汀20 mg/d治疗，对照组PCI术后当天开始用瑞舒伐他汀。分别于入院时、术前、术后24 h及术后28 d采集病人空腹静脉血，测定血清hsP、IL浓度入院时、术后28 d检测血脂浓度。结果 治疗组和对照组PCI术前IL和hs浓度与入院时比较，差异无显著性(t=0.925～1.362,Pgt0.05)PCI术后24 h及术后28 d两组IL和hs浓度较入院时均增高，差异有统计学意义(t=2.167～6.747,0.05)。治疗组入院时和术前IL、hs浓度与对照组比较，差异无统计学意义(t=0.320～0.910,Pgt0.05)术后24 h，治疗组IL、hs的浓度较对照组降低，差异有统计学意义(t=2.320、2.059，0.05)术后28 d，治疗组IL的浓度较对照组降低，差异有统计学意义(t=2.174，0.05),两组hs的浓度差异无统计学意义(t=0.201，Pgt0.05)。治疗组和对照组入院时和术后28 d的血脂浓度比较,差异均无统计学意义(t=0.522～1.322,Pgt0.05)。结论 PCI可以导致血清hs和IL水平升高早期应用瑞舒伐他汀可明显控制PCI术后血清hs、IL水平的上升，从而减少心血管事件的发生。 【关键词】 心绞痛瑞舒伐他汀血管成形术，经腔，经皮冠状动脉C反应蛋白白细胞介素18 [ABSTRACT] Objective To investigate the effect of rosvastatin on serum highy intervention (PCI). MethodsThis study included 40 patients with SA undergoing PCI, who were evenly randomized to treatment group and control group. A conventional therapy was offered to both groups. For those in treatment group, rosvastatin (20 mg/day) was added, starting from 7 days before PCI, and for those in the control, rosvastatin starting from the day of the procedure. The serum hsCRP,IL18 and lipids were measured on admission, before and 24 hours as well as 28 days after PCI. Results Preoperatively, the differences of hsCRP and IL18 between the two groups on admission were not significant (t=0.925-1.362,Pgt0.05). Postoperatively for 28 hours and 28 days, the levels of hsCRP and IL18 of the both groups were elevated, the difference being statistically significant compared with on admission (t=2.167-6.747,0.05). A comparison of levels of hsCRP and IL18 on admission and before PCI between the two groups was not significant (t=0.320-0.910,Pgt0.05). At 24 hours postoperatively, the levels of hsCRP and IL18 of the treatment group were lower than the control (t=2.320,2.0590.05). At 28 days postoperatively, the IL18 of the treatmen